RM LAW Announces Investigation of Urovant Sciences Ltd.

BERWYN, Pa., Nov. 18, 2020 /PRNewswire/ —  RM LAW, P.C. announces an investigation on behalf of Urovant Sciences Ltd. (“Urovant” or the “Company”) (NASDAQ: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant’s agreement to be acquired by Sumitovant Biopharma Ltd.

If you purchased shares of Urovant and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.

Under the terms of the agreement, Urovant’s shareholders will receive $16.25 in cash per share. 

For more information regarding this, please contact RM LAW, P.C.  (Richard A. Maniskas, Esquire) toll-free at (844) 291-9299 or by email at [email protected] or click here.   For more information about class action cases in general or to learn more about RM LAW, P.C. please visit our website by clicking here. 

RM LAW, P.C. is a national shareholder litigation firm.  RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

 

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/rm-law-announces-investigation-of-urovant-sciences-ltd-301176419.html

SOURCE RM LAW, P.C.